What is PerceptiMed?
PerceptiMed operates at the intersection of advanced technology and user experience optimization, focusing on delivering scalable solutions for both individual and enterprise-level clients. While the company maintains a lean operational profile, its strategic focus on innovative service delivery suggests a commitment to addressing critical inefficiencies in its target sectors. By prioritizing user-centric design and technological integration, PerceptiMed aims to carve out a distinct niche in a crowded digital ecosystem.
The firm is currently in a pivotal phase of its lifecycle, transitioning from foundational development to active market engagement. Through targeted outreach and a focus on high-value service offerings, PerceptiMed is building the necessary infrastructure to support rapid scaling and sustained growth in the coming fiscal periods.
How much funding has PerceptiMed raised?
PerceptiMed has raised a total of $10M across 5 funding rounds:
Unspecified
$3.1M
Unspecified
$499K
Private Equity
$5.4M
Debt
$350K
Debt
$642K
Unspecified (2012): $3.1M, investors not publicly disclosed
Unspecified (2013): $499K led by New Science Ventures
Private Equity (2014): $5.4M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Debt (2021): $642K backed by PPP
Key Investors in PerceptiMed
New Science Ventures
New Science Ventures is a venture capital firm specializing in early and late-stage investments within the life sciences and information technology sectors, focusing on novel scientific approaches.
PPP
Public-Private Partnership
Undisclosed Investor
A strategic partner contributing to the firm's private equity rounds to facilitate long-term growth and market penetration.
What's next for PerceptiMed?
With the recent infusion of $642K, PerceptiMed is poised to execute its next phase of strategic expansion. The company is expected to prioritize the refinement of its core product suite and the broadening of its customer acquisition channels. This capital allocation will likely facilitate deeper investment in R&D, ensuring that the firm remains at the forefront of technological innovation while maintaining the agility required to adapt to shifting market dynamics.
Looking ahead, the focus will remain on achieving operational milestones that justify the significant backing received to date. By aligning its product roadmap with the evolving needs of its enterprise clientele, PerceptiMed is well-positioned to transition into a mature market player, leveraging its strong financial foundation to drive long-term shareholder value and industry impact.
